Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey.

Fiche publication


Date publication

octobre 2021

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi


Tous les auteurs :
Kasi A, Dotan E, Poage GM, Catteau A, Vernerey D, George M, Barzi A

Résumé

Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk factors do not take the tumor immune microenvironment into account. Consideration of the Immunoscore, which measures the host immune response at the tumor site, may assist clinicians in reducing adjuvant chemotherapy use in patients who are unlikely to benefit from it. This study sought to determine the potential clinical utility of the Immunoscore, via its effect on medical oncologists' recommendations for management of patients with stage II colon cancer.

Mots clés

colonic neoplasms, oncologists, prognosis, surveys and questionnaires, tumor microenvironment

Référence

Cancers (Basel). 2021 Oct 30;13(21):